Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials. (19th May 2021)

• Record Type: Journal Article
• Authors: Joffe, Steven; Babiker, Abdel; Ellenberg, Susan S; Fix, Alan; Griffin, Marie R; Hunsberger, Sally; Kalil, Jorge; Levine, Myron M; Makgoba, Malegapuru W; Moore, Reneé H; Tsiatis, Anastasios A; Whitley, Richard
• Is Part Of: Journal of infectious diseases. Volume 224:Number 12(2021)
• Page Start: 1995
• Page End: 2000
• Publication Date: 2021-05-19
• Subjects: SARS-CoV-2 -- COVID19 -- clinical trials -- vaccines -- data and safety monitoring; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiab263
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: To speed the development of vaccines against SARS-CoV-2, the United States Federal Government has funded multiple phase 3 trials of candidate vaccines. A single 11-member data and safety monitoring board (DSMB) monitors all government-funded trials to ensure coordinated oversight, promote harmonized designs, and allow shared insights related to safety across trials. DSMB reviews encompass 3 domains: (1) the conduct of trials, including overall and subgroup accrual and data quality and completeness; (2) safety, including individual events of concern and comparisons by randomized group; and (3) interim analyses of efficacy when event-driven milestones are met. Challenges have included the scale and pace of the trials, the frequency of safety events related to the combined enrollment of over 100 000 participants, many of whom are older adults or have comorbid conditions that place them at independent risk of serious health events, and the politicized environment in which the trials have taken place. Abstract : The federal government has empaneled a data and safety monitoring board to oversee the SARS-CoV-2 vaccine trials that it funds. We describe the DSMB's mission and procedures and the challenges it has faced in overseeing these trials during a pandemic.